4KV4

Brd4 Bromodomain 2 in Complex with Acetylated Rel Peptide

4KV4 の概要

• エントリーDOI: 10.2210/pdb4kv4/pdb
• 関連するPDBエントリー: 4KV1
• 分子名称: Bromodomain-containing protein 4, Rel Peptide, 2,3-DIHYDROXY-1,4-DITHIOBUTANE, ... (4 entities in total)
• 機能のキーワード: rel, p65, bromodomain, transcription
• 由来する生物種: Homo sapiens (human); 詳細
• 細胞内の位置: Nucleus: O60885 Q04206
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 13929.29

構造登録者

Zhang, H.,Nair, S.K. (登録日: 2013-05-22, 公開日: 2013-06-26, 最終更新日: 2024-10-09)

主引用文献

Zou, Z.,Huang, B.,Wu, X.,Zhang, H.,Qi, J.,Bradner, J.,Nair, S.,Chen, L.F.
Brd4 maintains constitutively active NF-kappa B in cancer cells by binding to acetylated RelA.
Oncogene, 33:2395-2404, 2014

PubMed Abstract: Acetylation of the RelA subunit of NF-κB at lysine-310 regulates the transcriptional activation of NF-κB target genes and contributes to maintaining constitutively active NF-κB in tumors. Bromodomain-containing factor Brd4 has been shown to bind to acetylated lysine-310 (AcLys310) and to regulate the transcriptional activity of NF-κB, but the role of this binding in maintaining constitutively active NF-κB in tumors remains elusive. In this study, we demonstrate the structural basis for the binding of bromodomains (BDs) of bromodomain-containing protein 4 (Brd4) to AcLys310 and identify the BD inhibitor JQ1 as an effective small molecule to block this interaction. JQ1 suppresses TNF-α-mediated NF-κB activation and NF-κB-dependent target gene expression. In addition, JQ1 inhibits the proliferation and transformation potential of A549 lung cancer cells and suppresses the tumorigenicity of A549 cells in severe combined immunodeficiency mice. Furthermore, we demonstrate that depletion of Brd4 or treatment of cells with JQ1 induces the ubiquitination and degradation of the constitutively active nuclear form of RelA. Our results identify a novel function of Brd4 in maintaining the persistently active form of NF-κB found in tumors, and they suggest that interference with the interaction between acetylated RelA and Brd4 could be a potential therapeutic approach for the treatment of NF-κB-driven cancer.

PubMed: 23686307
DOI: 10.1038/onc.2013.179

実験手法

X-RAY DIFFRACTION (2 Å)